
CLAIMS

1. A compound of Formula (I):



Formula (I),

or a pharmaceutically acceptable salt thereof, wherein:

R is C_{1-30} alkyl, C_{2-30} alkenyl, C_{1-30} heteroalkyl, C_{2-30} heteroalkenyl, phenyl, heteroaryl, or amino acid moiety; and

R' is hydrogen, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{1-6} alkoxy, C_{1-6} heteroalkoxy, or C_{3-8} carbocyclyl.

2. The compound of claim 1, wherein:

(i) R' is hydrogen;

(ii) R' is C_{1-6} alkyl; and/or

(iii) R is C_{1-30} alkyl.

3. The compound of claim 1 or 2, wherein:


(i) R' is methyl; and/or

(ii) R is C_{11}-C_{19} alkyl.

4. The compound of any one of claims 1-3, wherein R is C_{13}-C_{17} alkyl.


5. The compound of any one of claims 1-4, wherein R is C_{15} alkyl or C_{17} alkyl.

6. The compound of any one of claims 1-5, wherein the compound is



or a pharmaceutically acceptable salt thereof.

7. The compound of any one of claims 1-5, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

8. The compound of any one of claims 1-7, wherein the pharmaceutically acceptable salt is a pamoate salt.

9. A nanoparticle, comprising a compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, and one or more polymer or surfactant.

10. The nanoparticle of claim 9, wherein:

(i) the pharmaceutically acceptable salt of the compound is a pamoate salt;

(ii) the one or more polymer or surfactant is an amphiphilic block copolymer; and/or

(iii) the diameter of the nanoparticle is about 100 nm to 1 μm.

11. The nanoparticle of claim 10, wherein the amphiphilic block copolymer comprises at least one block of poly(oxyethylene) and at least one block of poly(oxypropylene).

12. The nanoparticle of claim 9 or claim 10 , wherein said one or more polymer or surfactant is a poloxomer.

13.The nanoparticle of any one of claims 9-12, wherein the one or more polymer or surfactant:

(i) comprises a polyoxyethylene sorbitan fatty acid ester;

(ii) comprises polyethylene glycol (PEG); and/or

(iii) is P407.

14. The nanoparticle of any one of claims 9-13, wherein the one or more polymer or surfactant comprises:

(i) polyoxyethylene (20) sorbitan monolaurate; and/or

(ii) PEG 3350.

15. A pharmaceutical composition, comprising a compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, or a nanoparticle of any one of claims 9-14, and a pharmaceutically acceptable carrier.

16. Use of a compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, a nanoparticle of any one of claims 9-14, or a pharmaceutical composition of claim 15, in the manufacture of a medicament for treating drug addiction, drug dependence, drug overdose, opioid use disorder, pain, chronic pain, fibromyalgia, arthritis, or obesity.

17. The use of claim 16, wherein:

(i) the disease or disorder is opioid use disorder;

(ii) the compound, nanoparticle, or composition is administered via injection; and/or

(iii) the compound, nanoparticle, or composition is administered one time in a 1 to 12 month period.

18. The use of claim 16 or 17, wherein the compound, nanoparticle, or composition is administered one time in a 3, 6, 9, or 12 month period.